Clincosm LogoSign in Get a demo

Hypnosis for Chronic Idiopathic Pruritus

Sponsor
Centre Hospitalier Universitaire de Nice (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04829578
Collaborator
(none)
12
Enrollment
1
Arm
18
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Chronic idiopathic pruritus (CIP) is a frequent and disabling condition, for which there is no specific treatment. It was shown previously that hypnosis can relieve painful sensations. Pain and pruritus share many similarities regarding sensory receptors and pathways, suggesting that hypnosis might help relief CIP.

Condition or Disease Intervention/Treatment Phase
  • Other: Hypnosis
 N/A

Detailed Description

Chronic idiopathic pruritus (CIP) is a frequent and disabling condition, with significative impact on quality of life. At present, there is no specific treatment for CIP. Topical steroids are frequently used, with partial efficacy, and adverse effects. Hypnosis is a specific state of conscience. It differs from waking state, sleeping state, relaxation, or meditation. In this state, the person is highly responsive to suggestion. In medicine, hypnosis can be used to engage the internal resources of the person against unpleasant feelings. It was shown previously that hypnosis can relieve painful sensations. Pain and pruritus share many similarities regarding sensory receptors and pathways, suggesting that hypnosis might help relief CIP.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Prospective Study of Hypnosis for Chronic Idiopathic Pruritus
Anticipated Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Jul 1, 2021
Anticipated Study Completion Date :
Oct 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Hypnosis

hyspnosis treatment

Other: Hypnosis
Chronic idiopathic pruritus is treated by hypnosis

Outcome Measures

Primary Outcome Measures

  1. Change From Baseline in Pruritus Numeric Rating Scale [Day 84]

    Assessment of the intensity of pruritis in Pruritus Numeric Rating Scal; the minimum and maximum values 0 to 10

Secondary Outcome Measures

  1. Change From Baseline in Pruritus Verbal Rating Scale [Day 84]

    Assessment of Pruritus by pruritus Verbal Rating Scale; the minimum and maximum values 0 to 4

  2. Change From Baseline in Sleeping Scale [Day 84]

    assessment in sleeping scale ; the minimum and maximum values 0 to 10

  3. Change From Baseline in DLQI scale [Day 84]

    assessment in DLQI scale; result between 0 to 30

  4. Change From Baseline in HAD scale [Day 84]

    assessment in HAD scale; result between 0 to 42

  5. Change From Baseline in usage of topical steroids [Day 84]

    assessment in usage of topical steroids

  6. Evaluation of tolerance of hypnosis [Day 84]

    assessment of tolerance of hypnosis with report of adverse event

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Male or female of at least 18 years at screening

  • Diagnosis of chronic (at least 6 wks.) idiopathic pruritus

  • Pruritus Numeric Rating Scale > = 4

Exclusion Criteria:

  • Pruritus caused by a dermatological or a systemic conditions

  • Suicidal crisis, moderate, or severe

  • Psychosis (schizophrenia, persistent delusional disorder)

  • Bipolar disorder, not stabilized or decompensating

  • Personality disorder, decompensated

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Nice

Investigators

  • Principal Investigator: BAHADORAN PHILIPPE, Centre Hospitalier Universitaire de Nice

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:
NCT04829578
Other Study ID Numbers:
  • 20-AOIP-01
  • 2020-A03263-36
First Posted:
Apr 2, 2021
Last Update Posted:
Apr 2, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Pruritus

Study Results

No Results Posted as of Apr 2, 2021